A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone. The Phase III clinical trial studied participants with… Read More
Professor Dr Cornelis (‘Kees’) Melief has been awarded the 2022 Pedro J Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). The Award recognises individuals who have made immeasurable contributions and demonstrated outstanding commitment to the Journal for Immunotherapy of Cancer (JITC) and will be… Read More
News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022. Notably, it was a mixed week for PARP inhibitor olaparib, which was approved by regulator… Read More
Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a… Read More
The National Institute of Health and Care Excellence (NICE) has confirmed its decision not to recommend olaparib for previously treated metastatic prostate cancer in patients with BRCA gene mutations. The Institute of Cancer Research (ICR) has called the decision ‘disappointing’ and ‘frustrating’. It means that men in England and Wales… Read More
A study at Tel Aviv University is said to have eradicated glioblastoma, a highly aggressive type of brain cancer. The researchers were able to achieve this due to their discovery of two critical mechanisms in the brain that support tumour growth and survival. One protects cancer cells from the… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using pre|CISION technology so that it is activated predominantly in… Read More
GSK will present its latest gynaecological cancer research at the European Society for Medical Oncology (ESMO) Congress 2022 (September 9-13). The company will share positive trial data on its gynaecological cancer treatments Zejula (niraparib) and Jemperli (dostarlimab), as well as early-stage research in immuno-oncology and real-world evidence assessing treatment patterns… Read More
An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a recent study. The discovery was made by researchers at Washington University School of Medicine in St Louis, Grenoble Alpes University in Grenoble in France, and The University… Read More
Investment from Takeda ventures will fund the development of Zelluna Immunotherapy’s allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and,… Read More
The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More
A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in… Read More
The size of tumour and immune cell populations and their interactions over time impact outcomes to treatment. Immunotherapies that activate the immune system to seek and kill cancer cells have greatly improved outcomes for many patients with solid tumours. There is still, however, a subset of patients who do not… Read More
A new study by Qatar Foundation researchers from the Qatar Genome Research Consortium and Weill Cornell Medicine-Qatar has reported the first landscape of cancer germline variation – known as inherited cancer – in the Middle East. The study The study, led by Dr. Lotfi Chouchane… Read More
In this white paper, brought to you by BioRad, hear from leading industry experts in the emerging field of cancer vaccines. The experts discuss: Challenges related to antigen and adjuvant selection Vaccine design Immune response improvement Future treatment options Download the white paper here. Read More
Sonia Marsilio is an Associate Product Manager at Enzo. She explains how research tools enable scientists to accelerate immunotherapy. The growing, continuously evolving arsenal of cancer immunotherapies has changed the treatment landscape of many tumours. Dominating the space are the CAR T cell therapies, with CD19, BCMA, and CD22… Read More
